Search Results for: SPECIAL FEATURE Improving Bioavailability Solubili
EXCIPIENT UPDATE – Addressing Challenges With Low-Solubility Compounds: The Importance of Functional Excipients in the Formulation of Amorphous Dispersions October 12, 2012
Rod Ray, PhD, explains that because more than half of the compounds in early development are considered poorly soluble, improving oral bioavailability represents a significant challenge to the pharmaceutical industry.
SPECIAL FEATURE – Transdermal, Topical & Subcutaneous: Non-Invasive Delivery to Expand Product Line Extensions July 14, 2012
Contributor Cindy H. Dubin asked delivery system providers and contract developers and manufacturers to describe their products and service offerings in their respective areas of expertise and how they are changing the overall landscape of the transdermal, topical, and subcutaneous markets.
FORMULATION DEVELOPMENT – Formulating Immediate-Release Tablets for Poorly Soluble Drugs June 4, 2020
Gayatri Khanvilkar, MPharm, Ajit Bhagat, Sangmesh Torne, PhD, Tejas Gunjikar, PhD, and Amina Faham, PhD, present a case study showing that previously unviable APIs can be successfully processed with the right methods, which should give hope to formulators facing similar difficulties.
CONTROLLED RELEASE – Leveraging Precision Particle Fabrication® Technology to Create Patient-Friendly Dosage Forms May 2, 2017
Cory Berkland, PhD, and Nathan Dormer, PhD, review how controlled-release powders offer a flexible and efficient approach to addressing a multitude of patient populations, while also improving compliance.
Capsugel Investing in Enhanced Micronization Capacity & Capabilities September 12, 2016Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, recently announced an expansion of its facility in...
BUCCAL DELIVERY – Dissolvable Film Format Evolves to Buccal Drug Delivery Applications April 1, 2014
Scott D. Barnhart indicates the buccal and sublingual oral mucosa will continue to be an area of growing interest for drug delivery as researchers evaluate ways to improve bioavailability, patient compliance, and product lifecycle beyond tablet and injectable formats.